These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16874013)

  • 41. Strategies for selecting/switching chemotherapy and supportive care treatments during COVID-19 outbreak.
    Li Q; Hwang LC
    Cancer Med; 2020 Sep; 9(17):6079-6081. PubMed ID: 32779851
    [No Abstract]   [Full Text] [Related]  

  • 42. Dose: a critical factor in cancer chemotherapy.
    Frei E; Canellos GP
    Am J Med; 1980 Oct; 69(4):585-94. PubMed ID: 6999898
    [No Abstract]   [Full Text] [Related]  

  • 43. Editorial - Metronomic chemotherapy.
    Kumar MNVR; Sood AK
    Cancer Lett; 2017 Aug; 400():203. PubMed ID: 28315702
    [No Abstract]   [Full Text] [Related]  

  • 44. Dose-response relationship in experimental and clinical oncology.
    Brade WP; Freireich EJ; Goldin A
    Cancer Treat Rev; 1984 Dec; 11(4):279-83. PubMed ID: 6398757
    [No Abstract]   [Full Text] [Related]  

  • 45. Time-dose factors in chemotherapy: expanding the concept of dose-intensity.
    Dembo AJ
    J Clin Oncol; 1987 May; 5(5):694-6. PubMed ID: 3572462
    [No Abstract]   [Full Text] [Related]  

  • 46. High-time chemotherapy or high time for low dose.
    Kamen BA; Rubin E; Aisner J; Glatstein E
    J Clin Oncol; 2000 Aug; 18(16):2935-7. PubMed ID: 10944125
    [No Abstract]   [Full Text] [Related]  

  • 47. Guidelines for handling antineoplastic and immunosuppressive drugs.
    Watson AD; Peaston AE; Malik R; Swinney GR
    Aust Vet J; 1997 Dec; 75(12):868-76. PubMed ID: 9469220
    [No Abstract]   [Full Text] [Related]  

  • 48. [Perspectives of improvement of chemotherapy effectiveness in disseminated solid tumors].
    Sivashinskiĭ MS
    Vopr Onkol; 2004; 50(2):237-42. PubMed ID: 15176230
    [No Abstract]   [Full Text] [Related]  

  • 49. Why focus on the dose and schedule of chemotherapy?
    Ozer H
    Semin Oncol; 2004 Dec; 31(6 Suppl 15):1-2. PubMed ID: 15732194
    [No Abstract]   [Full Text] [Related]  

  • 50. A Cost-Focused Alternative Cancer Medication Dispensing Strategy-"Pack Splitting".
    Harvey RD; Ratain MJ
    JAMA Oncol; 2019 Dec; 5(12):1691-1692. PubMed ID: 31621807
    [No Abstract]   [Full Text] [Related]  

  • 51. Dose Schedules Inspired by Evolutionary Concepts Lengthen Progression-Free Survival in Mice.
    Schmidt C
    J Natl Cancer Inst; 2016 Jun; 108(6):djw157. PubMed ID: 27257024
    [No Abstract]   [Full Text] [Related]  

  • 52. Importance of chemotherapy scheduling: pieces of the puzzle.
    Hryniuk W
    Cancer Invest; 1999; 17(7):545-6. PubMed ID: 10518199
    [No Abstract]   [Full Text] [Related]  

  • 53. Individual variation in factors affecting the steps between dose application and effects of antineoplastic agents.
    Fuhr U; Kirchheiner J
    Int J Clin Pharmacol Ther; 2005 Dec; 43(12):573-4. PubMed ID: 16372521
    [No Abstract]   [Full Text] [Related]  

  • 54. Circadian rhythm and chemotherapy for cancer.
    Focan C
    Lancet; 1976 Sep; 2(7986):638-9. PubMed ID: 61380
    [No Abstract]   [Full Text] [Related]  

  • 55. Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit?
    Ratain MJ
    J Clin Oncol; 1998 Jul; 16(7):2297-8. PubMed ID: 9667242
    [No Abstract]   [Full Text] [Related]  

  • 56. Will increases in dose intensity improve outcome: pro.
    Hryniuk W
    Am J Med; 1995 Dec; 99(6A):69S-70S. PubMed ID: 8585543
    [No Abstract]   [Full Text] [Related]  

  • 57. Mathematical approaches to optimization of cancer chemotherapy.
    Zietz S; Nicolini C
    Bull Math Biol; 1979; 41(3):305-24. PubMed ID: 465827
    [No Abstract]   [Full Text] [Related]  

  • 58. Intensive cancer chemotherapy.
    Price LA; Hill BT
    Lancet; 1976 Nov; 2(7996):1195. PubMed ID: 63016
    [No Abstract]   [Full Text] [Related]  

  • 59. [Janus-faced character of chemotherapy: a comment on the Abel theses].
    Schmähl D
    Klin Wochenschr; 1991 Jan; 69(1):49-51. PubMed ID: 2016847
    [No Abstract]   [Full Text] [Related]  

  • 60. Phase IA/IB evaluation of mammalian cell-derived glycosylated recombinant human interleukin (SIGOSIX) before and after cytotoxic chemotherapy.
    Ritch PS; Keever C; Schiller J; Rivkin S; Witt PL; Grossberg SE; Truitt RL; Burris H; von Hoff DD; Vaickus L
    Ann N Y Acad Sci; 1995 Jul; 762():359-60. PubMed ID: 7668536
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.